You are here: vision-research.eu » News » Newsdetails:

News in Detail

Study shows drug reduces risk of relapse with neuromyelitis optica

The drug eculizumab, a synthetic antibody that inhibits the inflammatory response, significantly reduced the risk of relapse with neuromyelitis optica spectrum disorder (NMOSD).

This rare but severe autoimmune inflammatory disorder can cause blindness, paralysis and death.